Fate Therapeutics (FATE) Liabilities and Shareholders Equity (2012 - 2026)
Fate Therapeutics' Liabilities and Shareholders Equity came in at $260.1 million for Q2 2026, down 30.0% from $371.63 million a year earlier and down 8.7% from the prior quarter.
Powered by 
Analysis
Fate Therapeutics (FATE) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
At the end of FY2025, Fate Therapeutics' Liabilities and Shareholders Equity was $318.94 million, down 27.6% from FY2024.
- Liabilities and Shareholders Equity has declined in each of the last four years, with a five-year compound annual growth rate of -12.5% (FY2020 to FY2025).
- Going back by year, Liabilities and Shareholders Equity was $440.69 million in FY2024 (-12.9%), $506.22 million in FY2023 (-28.3%), $705.56 million in FY2022 (-23.4%) and $921.46 million in FY2021 (+48.0%).
- The Q2 2026 figure represents the lowest quarterly Liabilities and Shareholders Equity since Q2 2019.
- Year-over-year, Liabilities and Shareholders Equity has declined for 18 consecutive quarters, with an average decline of 24.8% over the last eight quarters.
- The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in Q3 2021 (growth of 57.2%), and the weakest in Q3 2025 (a decline of 30.6%).
- Business Quant data shows FATE's Liabilities and Shareholders Equity at $284.92 million (Q1 2026), $318.94 million (Q4 2025) and $343.67 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Fate Therapeutics | 276.57 Mn | 276.57 Mn | - | 260.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 260.10 Mn |
| Mar 31, 2026 | 284.92 Mn |
| Dec 31, 2025 | 318.94 Mn |
| Sep 30, 2025 | 343.67 Mn |
| Jun 30, 2025 | 371.63 Mn |
| Mar 31, 2025 | 398.67 Mn |
| Dec 31, 2024 | 440.69 Mn |
| Sep 30, 2024 | 494.97 Mn |
| Jun 30, 2024 | 528.82 Mn |
| Mar 31, 2024 | 569.89 Mn |
| Dec 31, 2023 | 506.22 Mn |
| Sep 30, 2023 | 543.79 Mn |
| Jun 30, 2023 | 584.76 Mn |
| Mar 31, 2023 | 630.34 Mn |
| Dec 31, 2022 | 705.56 Mn |
| Sep 30, 2022 | 749.35 Mn |
| Jun 30, 2022 | 807.06 Mn |
| Mar 31, 2022 | 858.39 Mn |
| Dec 31, 2021 | 921.46 Mn |
| Sep 30, 2021 | 984.57 Mn |
API Access
Fate Therapeutics Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=FATE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "FATE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=FATE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();